Yesterday, 4 senators introduced a bill on the Senate floor that would allow HHS to block drug price increases that it deems as “excessive.”
Yesterday, Senators Richard Blumenthal, D-Connecticut, Kamala Harris, D-California, Amy Klobuchar, D-Minnesota, and Jeff Merkley, D-Oregon, introduced a bill on the Senate floor, S. 3754, that would allow HHS to block drug price increases that it deems as “excessive.”
The bill, dubbed “A bill to prohibit price gouging in the sale of drugs,” is just the latest in a series of actions that Congressmen and the government alike have taken to address high drug prices.
In May 2018, the Trump administration released the “American Patients First” blueprint which contained 4 main strategies for decreasing drug prices, including increased competition, better negotiation, incentives for lower list prices, and reducing out-of-pocket costs. Since the release of the blueprint, the FDA approved more generic drugs in July 2018 than in any single month in its history.
Additionally, in July 2018 the FDA also released its Biosimilar Action Plan. The plan sought to improve the efficiency of the biosimilar development and approval process and support market competition through the reduction of anti-competitive practices that unfairly delay market entry. In 2018 alone, the FDA has approved 6 biosimilars of rituximab, epoetin alfa, adalimumab, pegfilgrastim, and filgrastim.
The administration took further action in October 2018 when HHS Secretary Alex Azar proposed requiring drug companies to include the list price of a drug paid for by Medicare or Medicaid in direct-to-consumer television advertising.
The proposal was met with pushback from industry trade group, Pharmaceutical Research and Manufacturers of America (PhRMA), when it announced that instead of including the list price within the advertisement, it would launch a “new platform that would provide patients, caregivers, and providers with cost and financial assistance information for brand-name medicines, as well as other patient support resources.” PhRMA also made clear to HHS that if such a requirement was made, it would raise significant legal questions, including First Amendment concerns.
Though 2018 has seen significant focus on reducing drug prices, more action is sure to come in 2019. According to Reuters, Democrat House of Representatives leader Nancy Pelosi, D-California, has promised to continue to work to tackle the issue of high drug prices when the newly-elected House is sworn in in January 2019.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.